2015

Contribution of Nrf2 to Atherogenic Phenotype Switching of Coronary Arterial Smooth Muscle Cells Lacking CD38 Gene

Ming Xu
Virginia Commonwealth University, China Pharmaceutical University, xum@vcu.edu

Xiao-Xue Li
Virginia Commonwealth University

Lei Wang
Virginia Commonwealth University, lei.wang@vcuhealth.org

See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/phtx_pubs

Part of the Medical Pharmacology Commons

This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.

Downloaded from
http://scholarscompass.vcu.edu/phtx_pubs/40

This Article is brought to you for free and open access by the Dept. of Pharmacology and Toxicology at VCU Scholars Compass. It has been accepted for inclusion in Pharmacology and Toxicology Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Contribution of Nrf2 to Atherogenic Phenotype Switching of Coronary Arterial Smooth Muscle Cells Lacking CD38 Gene

Ming Xu\textsuperscript{a,b} Xiao-Xue Li\textsuperscript{a} Lei Wang\textsuperscript{a} Mi Wang\textsuperscript{a} Yang Zhang\textsuperscript{a,c} Pin-Lan Li\textsuperscript{a}

\textsuperscript{a}Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA; \textsuperscript{b}Department of Clinical Pharmacy, School of Basic Medical and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China; \textsuperscript{c}Department of Pharmacological 
& Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas, USA

Key Words
CD38 • Dedifferentiation • Atherogenesis • Nrf2 • Vascular smooth muscle

Abstract

Background/Aims: Recent studies have indicated that CD38 gene deficiency results in dedifferentiation or transdifferentiation of arterial smooth muscle cells upon atherogenic stimulations. However, the molecular mechanisms mediating this vascular smooth muscle (SMC) phenotypic switching remain unknown. Methods & Results: In the present study, we first characterized the phenotypic change in the primary cultures of coronary arterial myocytes (CAMs) from CD38\textsuperscript{-/-} mice. It was shown that CD38 deficiency decreased the expression of contractile marker calponin, SM22α and α-SMA but increased the expression of SMC dedifferentiation marker, vimentin, which was accompanied by enhanced cell proliferation. This phenotypic change in CD38\textsuperscript{-/-} CAMs was enhanced by 7-ketocholesterol (7-Ket), an atherogenic stimulus. We further found that the CD38 deficiency decreased the expression and activity of nuclear factor E2-related factor 2 (Nrf2), a basic leucine zipper (bZIP) transcription factor sensitive to redox regulation. Similar to CD38 deletion, Nrf2 gene silencing increased CAM dedifferentiation upon 7-Ket stimulation. In contrast, the overexpression of Nrf2 gene abolished 7-Ket-induced dedifferentiation in CD38\textsuperscript{-/-} CAMs. Given the sensitivity of Nrf2 to oxidative stress, we determined the role of redox signaling in the regulation of Nrf2 expression and activity associated with CD38 effect in CAM phenotype changes. It was demonstrated that in CD38\textsuperscript{-/-} CAMs, 7-Ket failed to stimulate the production of O\textsubscript{2}•-, while in CD38\textsuperscript{+/+} CAMs 7-Ket induced marked O\textsubscript{2}•- production and enhancement of Nrf2 activity, which was substantially attenuated by NOX4 gene silencing. Finally, we demonstrated that 7-Ket-induced and NOX4-dependent O\textsubscript{2}•- production was inhibited by 8-Br-cADPR, an antagonist of cADPR or NED-19, an antagonist of NAADP as product of CD38 ADP-ribosylcyclase, which significantly inhibited the level of cytosolic Ca\textsuperscript{2+} and the activation of Nrf2 under 7-Ket. Conclusion: Taken together, these results suggest that CD38 activity is required for 7-Ket-induced Ca\textsuperscript{2+} and consequently O\textsubscript{2}•- production in CAMs, which increases Nrf2 activity to maintain their differentiated status.

M. Xu and X.-X. Li contributed equally to this work.

Pin-Lan Li, MD, PhD
Department of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, 1220 East Broad Street, P.O. Box 980613, Richmond, VA 23298, (USA)
Tel. 804 828-4793, Fax 804 828-2117, E-Mail pli@vcu.edu
When CD38 gene expression and function are deficient, the Nrf2 activity is suppressed, thereby leading to phenotypic switching of CAMs.

Introduction

Although vascular smooth muscle cells (VSMCs) undergo remarkable phenotypic switching during development and progression of vascular diseases such as atherosclerosis [1], the mechanism mediating this phenotypic changes of VASMCs remain poorly understood. Recent studies have indicated that CD38 is a multifunctional enzyme responsible for the production and metabolism of cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) in a variety of mammalian cells including VSMCs, which play important roles in the regulation of vascular function [2-4]. In particular, this CD38-mediated signaling pathway has been implicated in the regulation of cell differentiation of stem cell or tumor cell behaviors [5-6]. More recently, we demonstrated that the CD38 deficiency decreased contractile phenotype in CAMs and increased collagen deposition in coronary arterial wall from mice exposed to the high-fat Western diet [2]. It has been suggested that CD38 signaling pathway may play a critical role in the maintenance of the contractile phenotype in CAMs. However, it remains unknown how CD38 signaling pathway works to mediate this phenotypic change in CAMs.

Nuclear factor erythroid 2-related factor 2 (Nrf2), a basic leucine zipper transcription factor, plays a critical role in protecting cells from oxidative stress [7]. Some recent studies have reported that Nrf2 could be a new therapeutic target to prevent atherosclerosis [8-11]. Given previous reports that CD38 importantly controls NOX4-mediated intracellular O₂⁻ production in CAMs [12], it is likely that a redox-sensitive Nrf2 activity may be suppressed by deficient expression and function of CD38 and that Nrf2 may serve as a signaling mechanism to participate in phenotypic switching of CAMs when CD38 gene is lost or deficiently expressed.

To test this hypothesis, the present study used the primary cultures of CAMs to confirm that genetic deficiency of CD38 results in the switching of differentiated phenotype into atherogenic status in CAMs as shown by upregulation of dedifferentiated markers, enhanced proliferation, and production of extracellular matrix (ECM) proteins. This phenotypic switching was enhanced by 7-ketocholesterol (7-Ket), a prototype atherogenic stimulus abundant in oxidized low density lipoprotein (ox-LDL). Then, we went on to reveal that nucleus Nrf2 protein expression and activity are inhibited by the genetic deficiency of CD38 and that this inhibition of Nrf2 expression and activity contributes to the effect of CD38 deficiency in phenotype switching of CAMs. Lastly, we demonstrated that the mechanisms underlying Nrf2 inhibition in CAMs lacking CD38 gene are dependent upon NOX4-associated redox regulation.

Materials and Methods

Mice

Mice were purchased from the Jackson Laboratory. Eight-week old male and female mice were used in all experiments. All experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Virginia Commonwealth University.

Isolation and culture of mouse CAMs

CAMs were isolated from mice as previously described [13]. In brief, mice were deeply anesthetized with an intraperitoneal injection of pentobarbital sodium (25 mg/kg). The heart was excised with an intact aortic arch and immersed in a petri dish filled with ice-cold Krebs-Henseleit (KH) solution (in mM: 20 HEPES, 128 NaCl, 2.5 KCl, 2.7 CaCl₂, 1 MgCl₂, 16 glucose, pH 7.4). A 25-gauge needle filled with Hank’s buffered saline solution (HBSS) (in mM: 5.0 KCl, 0.3 KH₂PO₄, 138 NaCl, 4.0 NaHCO₃, 0.3 Na₂HPO₄, 7H₂O, 5.6 D-glucose, and 10 HEPES, with 2% antibiotics mixture) was inserted into the aortic lumen, while the whole heart remained in the ice-cold HBSS. The tip of the needle was inserted deep into the heart that
is approximate to the aortic valve. Then, the needle was tied in place with the needle tip as close to the base of the heart as possible. The infusion pump was started with a 20-ml syringe containing warm HBSS through an intravenous extension set at a rate of 0.1 ml/min for 15 min. HBSS was replaced with a warm enzyme solution (1 mg/ml collagenase type I, 0.5 mg/ml soybean trypsin inhibitor, 3% BSA, and 2% antibiotic-antimycotic mixture), which was flushed through the heart at a rate of 0.1 ml/min. Perfusion fluid was collected at 30-, 60-, and 90-min of perfusion. At 90 min, the heart was cut with scissors and the apex was opened to flush out the cells that collected inside the ventricle. The fluid was centrifuged at 1,000 rpm for 10 min, the cell-rich pellets were mixed with the one of the media described below, and the cells were plated on 2% gelatin-coated six-well plates and incubated in 5% CO₂-95% O₂ at 37°C. DMEM supplemented with 10% FBS, 10% mouse serum, and 2% antibiotics was used to culture isolated smooth muscle cells. The medium was replaced three days after cell isolation and then once or twice each week until the cells grew to confluence. As previously described [12], mouse CAMs were identified according to their morphology, immunohistological staining or Western blot analysis of marker proteins, and flow cytometric characteristics.

**Western blot analysis**

Western blot analysis was performed as we described previously [14]. In brief, proteins from the CAMs were extracted using sucrose buffer (20 mM HEPES, 1 mM EDTA, 255 mM sucrose, cocktail of protease inhibitors (Roche), pH 7.4). Nuclear protein was extracted from CAMs using a Cayman’s Nuclear Extraction Kit (Cayman 10009277) according to the manufacturer’s instruction. After boiling for 5 minutes at 95°C in a 5 × loading buffer, 30 μg of total proteins were separated by a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins of these samples were then electrophoretically transferred at 100 V for 1 hour onto a PVDF membrane (Bio-Rad, USA). The membrane was blocked with 5% nonfat milk in Tris-buffered saline with Tween 20. After washing, the membrane was probed with 1:1000 dilution of primary mouse or rabbit antibodies against vimentin (Santa Cruz), calponin (Santa Cruz), proliferating cell nuclear antigen (PCNA, Cell Signaling), smooth muscle 22 alpha (SM22α, Abcam), α-smooth muscle actin (α-SMA, Abcam), Nrf2 (Santa Cruz), NOX1 (Abcam), NOX4 (Santa Cruz), β-actin (Santa Cruz), or LamB1(Abcam) overnight at 4°C followed by incubation with horseradish peroxidase-labeled IgG (1:5000) against primary antibodies. The immuno-reactive bands were detected by chemiluminescence methods and visualized on Kodak Omat X-ray films. Densitometric analysis of the images obtained from X-ray films was performed using the Image J software (NIH).

**Proliferation assay**

The proliferation of CAMs was quantified using an Aqueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer’s instruction as we previously described [15]. Cells were cultured in a 96-well plate (2,000 cells per well) with or without treatment as indicated. After 48 hours, cells were incubated with 20 μL Aqueous One Solution for 60 min at 37°C. Then, the absorbance (at 490 nm) of each sample was measured using a microplate reader. Calibration curves showed the fluorescence reading to be proportional to the cell number. The proliferation rate was obtained by calculating the fold change in the cell number of each sample before and after 48-hour incubation.

**Measurement of Nrf2 activity**

Nrf2 activity was measured by an Nrf2 transcription factor assay kit (Cayman, 600590) according to the manufacturer’s instruction. Cayman’s Nrf2 transcription factor assay is a non-radioactive, colorimetric method for detecting specific transcription factor DNA binding activity in nuclear extracts. A specific double stranded DNA (dsDNA) sequence containing the Nrf2 response element is immobilized onto the wells of a 96-well plate. Nrf2 contained in nuclear extract samples will bind specifically to the Nrf2 response element. Nrf2 can be detected by addition of a specific Nrf2 antibody. A secondary antibody conjugated to HRP is added to provide a sensitive colorimetric readout at 450 nm. Nrf2 activity was expressed as the fold change of the treatment group versus the control.

**Immunofluorescent staining**

CAMs on a 8-well chamber slide were fixed with 4% paraformaldehyde (PFA) and then incubated with a blocking solution of 0.1% Triton X-100 in 5% bovine serum albumin (BSA). This was followed by incubation...
with anti-α-SMA (1:200, Abcam) or anti-Nrf2 (1:200, SantaCruz) primary antibody at 4°C overnight. After washing with phosphate-buffered saline containing 0.1% Tween-20 (PBST) three times, the slides were incubated with Alexa-555 secondary antibody (Life Technologies) for 1 hour at 37°C, and then mounted in Vector shield mounting medium with DAPI (Vector Laboratories Inc.). Staining was visualized through sequential scanning on an Olympus laser scanning confocal microscope (Fluoview FV1000, Olympus, Japan) or fluorescent microscopy (BX41TF, Olympus, Japan).

RNA interference

Small interference RNAs (siRNAs) were commercially available (QIAGEN, CA), and the sequences were as follows: For NOX1 siRNA: 5'-UGG AGU CAC UUU UUG UAC GAU-A-3', for NOX4 siRNA: 5'-UUU AGG GAC AGC CAA AUG AGC AGG-3’. Nrf2 siRNA were purchased from Santa Cruz (sc-37049). siRNAs of NOX1, NOX4 and Nrf2 have been demonstrated to efficiently inhibit the protein expression of NOX1, NOX4 and Nrf2 as we recently described [12, 16]. A scrambled small RNA (5'-AAU UCU CCG AAC GUG UCA GGU-3') was also confirmed no silencing of genes and used as a control in the present study. Transfection of siRNA was performed using the siLentFect Lipid Reagent (Bio-Rad, CA, USA) according to the manufacturer’s instructions, and the efficiency of siRNA to silence different genes was confirmed with Western blot analysis.

Electron spin resonance (ESR) detection of O$_2^-$

For detection of the O$_2^-$ production dependent on NADPH oxidase (NOX) in the membrane, CAMs were gently collected and resuspended in modified Krebs-Hepes buffer containing deferoxamine (100 μmol/L; Sigma, St. Louis, MO, USA) and diethylthiocarbamate (5 μmol/L; Sigma). These mixtures containing 1 × 10⁶ cells were subsequently mixed with 1 mM of the O$_2^-$ specific spin trap, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) in the presence or absence of manganese-dependent superoxide dismutase (SOD) (200 U/ml; Sigma). The mixtures were then loaded into glass capillaries and immediately analyzed for O$_2^-$ formation kinetics for 10 min in a Miniscope MS200 ESR spectrometer (Magnettech Ltd., Berlin, Germany) as described [12]. The ESR settings were as follows: biofield, 3350; field sweep, 60 G; microwave frequency, 9.78 GHz; microwave power, 20 mW; modulation amplitude, 3 G; 4096 points of resolution; receiver gain, 50 for cells. The SOD-sensitive O$_2^-$ was calculated as specific signal of NOX activity. The results were expressed as the fold change of the treatment group versus the control.

Nucleofection of CD38 cDNA and Nrf2 cDNA

Both CD38 cDNA (Catalog# MG204265) and Nrf2 cDNA plasmids (Catalog# MG226717) were purchased from OriGene Technologies. Transfection of plasmids was performed using a 4D Nucleofector X-Unit (Lonza, CA, USA) according to the manufacturer’s instructions, which was described in our recent studies [2]. Briefly, CAMs were trypsinized and centrifuged at 90g for 10 minutes. The cell pellet was resuspended in 100 μL P1 Nucleofection solutions (Lonza) for Nucleofection (with the program code CM137). The program was chosen based on the fact that Nucleofection efficiency was over 80% as analyzed by flow cytometry using control GFP plasmids. For each Nucleofection sample, 2 μg plasmid DNA was added in 100 μL P1 Nucleofection solution. After Nucleofection, the cells were cultured in the DMEM medium for 24 hours and then were ready for treatment. The efficiency of CD38 cDNA and Nrf2 cDNA transfection was assessed by Western blot analyses [17].

Fluorescent microscopic measurement of [Ca$^{2+}$] in CAMS

A fluorescence image analysis system was used to determine [Ca$^{2+}$], in CAMs with fura-2 acetoxyethyl ester (fura-2) as an indicator as previously described [14]. Having been loaded with 10 μM fura-2 at room temperature for 30 min, the cells were washed three times with Ca$^{2+}$-free Hank’s buffer. The ratio of fura-2 emissions, when excited at the wavelengths of 340 and 380 nm, was recorded with a digital camera (Nikon Diaphot TMD Inverted Microscope). Metalfura imaging and analysis software were used to acquire, digitize, and store the images for off-line processing and statistical analysis (Universal Imaging). The fluorescence ratio of excitation at 340 nm to that at 380 nm (F340/F380) was determined after background subtraction, and [Ca$^{2+}$], was calculated by using following equation: [Ca$^{2+}$] = K R / [(R - R$^{\text{min}}$)/(R - R)], where K is the fluorescence ratio at fura-2-Ca$^{2+}$ complex is 224 nM; R is the fluorescence ratio (F$^{\text{max}}$/F$^{\text{min}}$); R$^{\text{max}}$ and R$^{\text{min}}$ are the maximal and minimal fluorescence ratios measured by addition of 10 μM of Ca$^{2+}$ ionophore ionomycin to Ca$^{2+}$-replete solution (2.5 mM CaCl$_2$) and Ca$^{2+}$-free solution (5 mM EGTA), respectively; and β is the fluorescence ratio at 380-nm excitation determined at R$^{\text{max}}$ and R$^{\text{min}}$ respectively.
Statistics
Data are presented as means ± SE. Significant differences between and within multiple groups were examined using ANOVA for repeated measures, followed by Duncan’s multiple-range test. The Student’s t test was used to detect significant differences between two groups. P<0.05 was considered statistically significant.

Results

Phenotypic characterization in CD38-/ CAMs
A hallmark feature of VSMC phenotypic switching is featured by altered expression of VSMC selective contractile genes, including calponin, SM22α and α-SMA [18]. To examine whether CD38 regulates phenotypic switching in CAMs, CD38 gene knockout (CD38-/ ) CAMs were used to compare with wild-type (CD38+/+) CAMs. As showed in Fig. 1A and 1B, the CD38 deficiency significantly decreased the protein level of calponin and SM22α, which was enhanced by 7-Ket in CAMs. Representative fluorescent images in Fig. 1E also showed that the fluorescent intensity of a contractile phenotype marker α-SMA decreased in CD38-/ CAMs compared with that in CD38+/+ CAMs, particularly when they were treated with 7-Ket.

Conversely, the decrease of proteins associated with the contractile phenotype was generally accompanying by the increased dedifferentiation marker vimentin in CD38-/ CAMs (Fig. 1C). The levels of PCNA, an excellent marker for cell proliferation, also increased in CD38-/ CAMs under control and 7-Ket stimulation when compared with that from CD38+/+ CAMs (Fig. 1D). As shown in Fig. 1F, the proliferation rate of CAMs measured using an Aqueous

Fig. 1. Phenotypic characterization in CD38-/ CAMs. CAMs from CD38+/+ and CD38-/ mice were treated with atherogenic stimulus, 7-ketocholesterol (7-Ket, 10 µg/ml) for 24 hours. Representative Western blot gel documents and summarized data showing the protein expression of calponin (A), SM22α (B), vimentin (C), and PCNA (D). (E) Typical representative fluorescent images for α-SMA staining. (F) Summarized data showing the proliferation rate of CAMs in CD38+/+ and CD38-/ CAMs. P<0.05, CD38+/+ treated vs. CD38+/+ control; * P<0.05, CD38+/+ vs. CD38-/ CAMs (n=6).
One Solution Cell Proliferation Assay kit markedly increased in CD38 deficiencies compared to CD38+/+ cells, which enhanced by 7-Ket (Fig. 1F).

**CD38 deficiency inhibited the activation of Nrf2**

To gain further insights into the molecular mechanisms underlying the phenotypic switching due to lack of CD38 in CAMs, the possible involvement of transcription factor, Nrf2 was examined as a downstream regulator. Since Nrf2 activation is dependent on its translocation in nuclei to activate expression of its target genes, we first attempted to examine the nuclear accumulation of Nrf2 protein. As shown in Fig. 2A, the nuclear Nrf2 protein level dramatically decreased in CD38−/− CAMs compared with CD38+/+ CAMs under 7-Ket treatment. In contrast, CD38 overexpression by transfection of CD38 full length cDNA restored the protein level of nuclear Nrf2 in CD38−/− CAMs (Fig. 2B).

The nuclear translocation of Nrf2 from cytosol under 7-Ket was confirmed by immunolocalization of anti-Nrf2 antibody using Fluorescent microscopy (Fig. 2C). The assay of Nrf2 activity was performed using Cayman’s Nrf2 transcription factor assay kit. As shown in Fig. 2D, the nuclear Nrf2 activity was dramatically decreased in CD38−/− CAMs under 7-Ket stimulation. All these data strongly suggest that the activation of Nrf2 upon 7-Ket stimulation is dependent on the normal expression of CD38 gene.
Nrf2 deficiency changed the phenotypic marker in CAMs

To elucidate the role of Nrf2 on phenotypic switching in CAMs, we next examined whether CAMs lacking Nrf2 exhibit a more proliferative status. Nrf2 siRNA was transfected into CAMs and the phenotypic markers described above were observed. We have demonstrated that Nrf2 siRNA inhibit the protein expression of Nrf2 by 57.4% (Fig. 3A). As showed in Fig. 4A and 4B, Nrf2 deficiency resulted in a significant decrease in the protein level of calponin and SM22α as well as in α-SMA fluorescent staining under 7-Ket stimulation (Fig. 4E). Conversely, 7-Ket-induced vimentin expression and PCNA were further augmented in CAMs with silencing of Nrf2 gene (Fig. 4C and 4D), accompanied with an increase in proliferation rate of CAMs in response to 7-Ket stimulation (Fig. 4F).

To further confirm the Nrf2 on phenotypic change in CAMs, Nrf2 full length cDNA plasmids were transfected into CD38−/− CAMs. We have demonstrated that Nrf2 cDNA increased the protein expression of Nrf2 by 2.42-fold (Fig. 3B). As showed in Fig. 5A-F, Nrf2 overexpression restored the expression of phenotypic markers and cell proliferation observed in CD38−/− CAMs. These results suggest that Nrf2 determines the proliferative phenotype in CD38−/− CAMs.

The effect of NOX4 gene silencing on Nrf2 translocation into the nucleus

We demonstrated that CD38 importantly controls NAD(P)H oxidase-mediated intracellular O₂⁻ production in CAMs[12]. Here, we found that NOX4 protein expression decreased in CD38−/− CAMs compared with CD38+/+ CAMs (Fig. 6A). However, there was no significant difference in NOX1 protein expression between CD38−/− and CD38+/+ CAMs under control and 7-Ket treatment (Fig. 6B). By using the ESR spectrometry, we further determined that 7-Ket markedly induced O₂⁻ production, which was almost blocked in CD38−/− CAMs (Fig. 6C). We demonstrated that NOX1 and NOX4 siRNA inhibit the protein expression of NOX1.
and NOX4 by 66.5% and 77.4%, respectively [12]. Here we found that NOX4 siRNA, not NOX1 siRNA significantly inhibited $O_2^-$ production induced by 7-Ket (Fig. 6D).

In addition, using fluorescent microscopy we found that Nrf2 translocation decreased in CAMs transfected with NOX4 siRNA (Fig. 6E). Similarly, Nrf2 activity was also significantly inhibited in CAMs transfected with NOX4 siRNA (Fig. 6F). Taken together, these results clearly indicate that NOX4-dependent $O_2^-$ production controls Nrf2 activation.

**Contribution of cADPR or NAADP-sensitive Ca$^{2+}$ signaling to $O_2^-$ production**

CD38 functions as a multifunctional enzyme that produces cADPR and NAADP, potent intracellular Ca$^{2+}$ mobilizers [4]. To demonstrate the effect of CD38-dependent Ca$^{2+}$ signaling on the elevation of $O_2^-$ and subsequently Nrf2 nuclear translocation, we incubated CAMs with cADPR antagonist, 8-Br-cADPR, or NAADP antagonist, NED-19 which significantly inhibited the level of cytosolic Ca$^{2+}$ under 7-Ket (Fig. 7A and B). Importantly, Fig. 7C showed that 8-Br-cADPR or NED-19 significantly inhibited 7-Ket-induced NOX-dependent $O_2^-$ production. We also observed nuclear translocation of Nrf2 and Nrf2 activity in 7-Ket-treated cells, which were inhibited in the presence of 8-Br-cADPR or NED-19 (Fig. 7D, E). These results demonstrate the role of cADPR or NED-19-sensitive Ca$^{2+}$ signaling in the control of $O_2^-$ production, which contributes to the activation of Nrf2.

**Discussion**

In the present study, we provided novel evidences that a redox-sensitive transcription factor, Nrf2 plays an important role in 7-Ket stimulated phenotypic switching of CAMs (see working model in Fig. 8). This Nrf2-mediated action is critical for the occurrence of
proliferative and atherosclerotic phenotype when CD38 gene was silenced or deleted. Furthermore, we confirmed that CD38-derived enzyme product cADPR and NAADP and associated Ca$^{2+}$ signaling mechanisms are importantly implicated in the control of Nrf2 activation through NOX4-dependent $O_2^{-}$ production.

The arterial SMCs within atherosclerotic lesions undergo phenotypic modulation and migration into the intima, where they proliferate, produce extracellular matrix, and participate in fibrous cap formation [19]. However, the mechanisms that control arterial SMC phenotypic switching remain poorly understood. In a previous study, we have demonstrated that CAMs from CD38$^{-/-}$ mice had an enhanced dedifferentiated phenotype upon atherogenic stimulations compared to that from CD38$^{+/+}$ mice [2]. In the present study, we also demonstrated increased expression of dedifferentiation markers and decreased expression of contractile phenotype markers in CD38$^{-/-}$ CAMs under atherogenic stimulations. These results in vivo and in vitro strongly indicate that CD38 is a critical enzyme for the control of CAMs phenotype during atherosclerotic lesions. It is imperative to explore the molecular mechanisms by which CD38-mediated signaling controls phenotype changes in CAMs.

It was shown that CD38 gene deletion decreased the expression of Nrf2 and reduced nuclear Nrf2 activity and translocation in CAMs upon atherogenic stimuli. This for the first time links CD38 and Nrf2 in CAMs, suggesting that Nrf2 is involved in pathological changes.

**Fig. 6.** NOX4-dependent $O_2^{-}$ is responsible for Nrf2 translocation into the nucleus. Representative Western blot documents and summarized data showing the protein expression of NOX4 (A) and NOX1 (B) in CD38$^{+/+}$ and CD38$^{-/-}$ CAMs treated with 7-Ket. (C) Summarized ESR data showing the relative $O_2^{-}$ production in CD38$^{+/+}$ and CD38$^{-/-}$ CAMs under control and treatment with 7-Ket. *P<0.05, CD38$^{+/+}$ treated vs. CD38$^{-/-}$ control; a P<0.05, CD38$^{+/+}$ vs. CD38$^{-/-}$ CAMs. (n=6). (D) Summarized ESR data showing the relative $O_2^{-}$ production (SOD sensitive $O_2^{-}$) in CD38$^{+/+}$ CAMs transfected with NOX4 siRNA and NOX1 siRNA. (E) Typical representative fluorescent images for nuclear translocation of Nrf2 in CAMs transfected with NOX4 siRNA. (D) Summarized data showing nuclear Nrf2 activity of CAMs transfected with NOX4 siRNA. *P<0.05, vs. Scramble control; † P<0.05, vs. Scramble 7-Ket (n=6).
in different vascular cells during atherosclerosis. Recently, it has been reported that geraniol dietary or ellagic acid protects against atherosclerosis by Nrf2 activation in diet-induced experimental atherosclerosis [8, 20, 21]. In addition, shear force on arterial endothelial cells strongly activated Nrf2 and induced its nuclear translocation, thereby promoting athero-protective gene expression and related endothelial adaptation [11, 22]. However, there are some reports that disruption of Nrf2 exhibited significantly smaller plaque area in ApoE-mediated atherosclerosis in mice due to upregulation of CD36 [23]. It seems that the activation of Nrf2 during atherogenesis may play a dual role including anti- and proatherogenic role, which is associated with the experimental model and its action on different vascular beds.

**Fig. 7.** cADPR or NAADP-sensitive Ca\(^{2+}\) regulates O\(_2^\cdot\) Production. CAMs were pretreated with 8-Br-cADPR (30 µM) or NED-19 (10 µM) and then stimulated with 7-Ket for 24 hours. Representative Ca\(^{2+}\) traces (A) and summarized data (B) showing the level of cytosolic Ca\(^{2+}\) in CAMs. (C) Summarized ESR data showing the relative O\(_2^\cdot\) production in CAMs before and after treatment with 8-Br-cADPR or NED-19. (D) Typical representative fluorescent images showing nuclear translocation of Nrf2 in CAMs pretreated with 8-Br-cADPR or NED-19. (E) Summarized data showing nuclear Nrf2 activity in CAMs pretreated with 8-Br-cADPR or NED-19. *P<0.05, vs. control; †P<0.05, vs. CAMs treated with 7-Ket (n=6).

**Fig. 8.** Working model in this project. In this model, Nrf2 plays an important role in the occurrence of proliferative and atherosclerotic phenotype when CD38 gene was silenced or deleted. CD38-derived enzyme product cADPR and NAADP and associated Ca\(^{2+}\) signaling mechanisms are importantly implicated in the control of Nrf2 activation through NOX4-dependent O\(_2^\cdot\) production.
In this regard, it was reported that Nrf2 regulates VSMCs migration and neointimal in vitro, and it alters the susceptibility of VSMCs to atherogenic stimuli [24]. However, a direct role of Nrf2 in phenotypic switching of these VSMCs has not been determined. In the present study, we determined the critical role of Nrf2 in phenotypic switching of CAMs by knocking down its gene, which mimicked the effects of CD38 deficiency on phenotypic switching in these CAMs. Moreover, we found that Nrf2 gene overexpression restored the phenotypic switching in CD38-/- CAMs. These results support the view that Nrf2 functions as a key regulator for CD38-dependent phenotypic switching in CAMs upon the atherogenic stimulations. In previous studies, Nrf2 gene overexpression was also found to suppress human or rabbit aortic smooth muscle cell proliferation in vitro [25]. In other studies, the activation of Nrf2 has been shown to regulate the basal and inducible expression of cytoprotective, detoxifying and antioxidant genes[26] and that Nrf2-ARE-oxidoreductase-1 (NQO1) pathway may importantly contribute to the inhibition of the major molecules that lead to vascular damage and VSMCs proliferation and migration [10].

To further test how Nrf2 activity or translocation is altered by atherogenic stimuli in CD38 deficient CAMs, we examined the role of CD38 associated with redox signaling. NOX1, NOX2 and NOX4 were identified in vascular cells such as endothelial and smooth muscle cells[27]. However, in our previous studies and by others demonstrated that NOX2 had no significant action on extracellular and intracellular O2·- production in response to ANG II or oxotremorine [12, 28, 29]. In these studies, we have demonstrated that NOX1 primarily contribute to extracellular O2·- production, but CD38 importantly controls NOX4-mediated intracellular O2·-production in CAMs [12]. It is possible that O2·- derived from NOX4 contributes to CD38-dependent Nrf2 activation in CAMs. Since our previous studies have also found that CD38-regulated intracellular O2·- production is primarily dependent on intracellular NOX4 activity [12], the present study addressed whether Nrf2-mediated phenotypic switching of CD38-/- CAMs upon atherogenic stimuli is attributed to NOX4-dependent O2·- production. It was found that 7-Ket failed to stimulate the production of O2·- in CD38+/+ CAMs, but indeed induced marked O2·- production and enhancement of Nrf2 activity in CD38-/- CAMs. This O2·- production and consequent enhancement of Nrf2 activity in CD38-/- CAMs were substantially attenuated by NOX4 gene silencing, but not by NOX1 knocking down. These results provide convincing evidence that NOX4 derived O2·- regulates Nrf2 activity and thereby determines the phenotypic transition of CAMs into proliferative and sclerotic status. Although we did not attempt to test how O2·- regulates Nrf2 activity, previous studies have shown that Nrf2 translocation to the nucleus and its activity are related to the action O2·- to target the Nrf2-Keap1 complex [30, 31]. Under resting conditions, Keap1 plays a critical role in the control of Nrf2 levels in the cells[32]. O2·- target the Nrf2-Keap1 complex, dissociating Nrf2 from Keap1[33]. Stabilized Nrf2 is then translocated into the nucleus, where it transactivates related target genes. In CAMs, this regulation of Nrf2 translocation or function is dependent upon NOX4-dependent O2·- production, but not NOX1-derived O2·- despite that NOX1 has been shown to be enriched in membrane fraction to mainly produce extracellular O2·- [28].

Finally, we further explored the mechanism mediating NOX4-dependent O2·- production in CAMs upon atherogenic stimulations. Previous studies have shown that NOX4 activity is sensitive to intracellular Ca2+ levels associated with cADPR-induced Ca2+ release from ryanodine receptor, a Ca2+ channel on the SR membrane [34]. Therefore, it is possible that CD38-derived cADPR production induces Ca2+ mobilization from the SR and thereby results in local activation of NOX4 on the SR. The current study indeed demonstrated that cADPR from CD38-cyclic ADP-ribosylcyclase was involved in 7-Ket-induced Ca2+ release. Furthermore, cADPR-dependent Ca2+ release was shown to regulate Nrf2 activation. In addition, NAADP, another product from CD38-cyclic ADP-ribosylcyclase was also involved in 7-Ket-induced Ca2+ release to regulate Nrf2 activation. These findings provide direct evidence that cADPR or NAADP-induced intracellular Ca2+ mobilization contributes to the activation of Nrf2 in CAMs.

In conclusion, we demonstrated that upon atherogenic stimulation CD38 activity is required for 7-Ket-induced O2·- production, which increases Nrf2 activity to maintain CAMs
in a differentiated status. When CD38 gene expression and function are deficient, the Nrf2 activity is suppressed via NOX4-dependent $O_2^-$ production leading to dedifferentiation of CAMs.

Acknowledgments

This study was supported by grants from the National Institutes of Health (HL 057244, HL075316, HL091464, and HL122937).

Disclosure Statement

None.

References

Xu et al.: Nrf2 in Atherogenic Phenotype Switching of Arterial Myocytes


